Doseology's New Executive Chairman: Larry Latowsky Enhances Governance and Growth Strategy
On February 20, 2026, Doseology Sciences Inc., a company prominent in developing innovative oral delivery systems, made a significant announcement regarding its organizational structure with the appointment of Larry Latowsky as Executive Chairman of the Board of Directors, effective February 18. Latowsky will play a crucial role in guiding Doseology as it navigates the burgeoning market for oral stimulants, which is poised for significant growth due to increasing demand for controlled consumption products.
Doseology is focused on creating precision-controlled oral delivery systems that fall within the emerging category of oral stimulants. The company's design philosophy is centered on harm reduction which aims to ensure that products not only maintain effectiveness but do so in a manner that emphasizes consumer safety and predictability. As Doseology prepares for commercialization and expansion efforts, it seeks to establish a robust foundation in areas such as governance, intellectual property rights, and systematic delivery mechanisms.
Larry Latowsky's appointment is seen as a strategic move to enhance the company’s governance and to fortify its market strategy. His extensive experience in public markets, as well as running comprehensive health-related enterprises, positions him to significantly contribute to Doseology's growth trajectory. Having vast experience in public oversight and dealing with institutional investors, his leadership is expected to bolster Doseology's credibility within capital markets, aligning with the company's goal to evolve from early innovation to broader market engagement.
In conjunction with his new position, Latowsky has been allotted 4,000 restricted share units (RSUs) and 6,000 performance share units (PSUs), which will vest based on certain performance metrics and over a timeframe of 36 months. This aligns his interests closely with shareholder value and sets a performance-based expectation for his role within the company.
Operating within a landscape characterized by the maturity of regulated oral stimulant formats in European markets, Doseology is leveraging insights from these established markets as it builds its product portfolio in North America. The North American market is currently fragmented with limited players, creating a unique opportunity for Doseology to carve out a significant share. By focusing on disciplined execution and thoughtful innovation, the company seeks to position itself effectively amid evolving consumer preferences toward safer and more effective stimulant solutions.
Latowsky's qualifications include his education from the University of Toronto and the Institute of Corporate Directors of Canada, alongside a robust career in corporate governance where he has served on various for-profit and non-profit boards. His previous role as President and CEO of Katz Group Canada, which operates one of Canada's largest pharmacy chains, lends essential operational insights to Doseology, notably in enhancing company attractiveness for future investments and acquisitions. Under his leadership, Katz Group was sold to McKesson Corporation for approximately C$3 billion, underscoring his ability to successfully manage high-stakes corporate transitions.
Additionally, as former Chairman of Well.ca, Latowsky’s involvement in e-commerce within the health sector equips him with insights into scaling operations effectively in a digital and direct-to-consumer marketplace. His executive experience with renowned pharmaceutical distribution platforms such as Drug Trading Company and DC Labs further underscores his capability in handling production and distribution under regulated environments, a focal point for Doseology's operational strategy moving ahead.
Chris Jackson, the CEO of Doseology Sciences, commented on Latowsky’s appointment, stating that it consolidates the company's strategic ambitions at a critical phase. With a clearly defined strategy and a committed team, the company is confident in Latowsky's ability to guide Doseology towards meaningful growth while creating long-term value for its stakeholders.
Latowsky expressed his enthusiasm for joining the Doseology team, citing his attraction to the company’s clear strategic vision set against a backdrop of disciplined execution. He emphasized his confidence in not only the potential of the emerging category of oral stimulants but also in the team’s ability to leverage collective networks to create sustainable value in the long run.
As Doseology moves forward under this new leadership structure, it represents a promising era defined by strategic governance and a focus on delivering innovative, safe, and effective oral stimulant products, distinguishing itself in the competitive health product market.
About Doseology Sciences Inc.:
Doseology Sciences Inc. is an innovative company focused on precision-controlled oral delivery systems within the oral stimulant sector, combining science-backed methodologies with harm-reduction principles to ensure safety and effectiveness in consumer manipulation of stimulants.
For more information, visit: doseology.com or feedthatbrain.com.
Doseology is focused on creating precision-controlled oral delivery systems that fall within the emerging category of oral stimulants. The company's design philosophy is centered on harm reduction which aims to ensure that products not only maintain effectiveness but do so in a manner that emphasizes consumer safety and predictability. As Doseology prepares for commercialization and expansion efforts, it seeks to establish a robust foundation in areas such as governance, intellectual property rights, and systematic delivery mechanisms.
Larry Latowsky's appointment is seen as a strategic move to enhance the company’s governance and to fortify its market strategy. His extensive experience in public markets, as well as running comprehensive health-related enterprises, positions him to significantly contribute to Doseology's growth trajectory. Having vast experience in public oversight and dealing with institutional investors, his leadership is expected to bolster Doseology's credibility within capital markets, aligning with the company's goal to evolve from early innovation to broader market engagement.
In conjunction with his new position, Latowsky has been allotted 4,000 restricted share units (RSUs) and 6,000 performance share units (PSUs), which will vest based on certain performance metrics and over a timeframe of 36 months. This aligns his interests closely with shareholder value and sets a performance-based expectation for his role within the company.
Operating within a landscape characterized by the maturity of regulated oral stimulant formats in European markets, Doseology is leveraging insights from these established markets as it builds its product portfolio in North America. The North American market is currently fragmented with limited players, creating a unique opportunity for Doseology to carve out a significant share. By focusing on disciplined execution and thoughtful innovation, the company seeks to position itself effectively amid evolving consumer preferences toward safer and more effective stimulant solutions.
Latowsky's qualifications include his education from the University of Toronto and the Institute of Corporate Directors of Canada, alongside a robust career in corporate governance where he has served on various for-profit and non-profit boards. His previous role as President and CEO of Katz Group Canada, which operates one of Canada's largest pharmacy chains, lends essential operational insights to Doseology, notably in enhancing company attractiveness for future investments and acquisitions. Under his leadership, Katz Group was sold to McKesson Corporation for approximately C$3 billion, underscoring his ability to successfully manage high-stakes corporate transitions.
Additionally, as former Chairman of Well.ca, Latowsky’s involvement in e-commerce within the health sector equips him with insights into scaling operations effectively in a digital and direct-to-consumer marketplace. His executive experience with renowned pharmaceutical distribution platforms such as Drug Trading Company and DC Labs further underscores his capability in handling production and distribution under regulated environments, a focal point for Doseology's operational strategy moving ahead.
Chris Jackson, the CEO of Doseology Sciences, commented on Latowsky’s appointment, stating that it consolidates the company's strategic ambitions at a critical phase. With a clearly defined strategy and a committed team, the company is confident in Latowsky's ability to guide Doseology towards meaningful growth while creating long-term value for its stakeholders.
Latowsky expressed his enthusiasm for joining the Doseology team, citing his attraction to the company’s clear strategic vision set against a backdrop of disciplined execution. He emphasized his confidence in not only the potential of the emerging category of oral stimulants but also in the team’s ability to leverage collective networks to create sustainable value in the long run.
As Doseology moves forward under this new leadership structure, it represents a promising era defined by strategic governance and a focus on delivering innovative, safe, and effective oral stimulant products, distinguishing itself in the competitive health product market.
About Doseology Sciences Inc.:
Doseology Sciences Inc. is an innovative company focused on precision-controlled oral delivery systems within the oral stimulant sector, combining science-backed methodologies with harm-reduction principles to ensure safety and effectiveness in consumer manipulation of stimulants.
For more information, visit: doseology.com or feedthatbrain.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.